<DOC>
	<DOCNO>NCT01330472</DOCNO>
	<brief_summary>Study evaluate Xanax sustain release tablet manufacture two different site provide similar drug level blood .</brief_summary>
	<brief_title>An Bioequivalence Study Of Xanax Extended Release Tablets From Two Different Manufacturing Sites</brief_title>
	<detailed_description />
	<mesh_term>Alprazolam</mesh_term>
	<criteria>Healthy male and/or female subject age 20 55 year , inclusive . An informed consent document sign date subject . Evidence history clinically significant abnormality . A positive urine drug screen . Subjects hypersensitive alprazolam related compound .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Alprazolam</keyword>
	<keyword>Xanax</keyword>
	<keyword>Bioequivalence</keyword>
	<keyword>Panic disorder without agoraphobia .</keyword>
</DOC>